DoD Multiple Sclerosis, Clinical Trial Award
ID: 353635Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353635
Timeline
    Description

    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Multiple Sclerosis Clinical Trial Award (MSRP CTA) to support innovative clinical trials aimed at improving the treatment and management of multiple sclerosis (MS). This grant opportunity invites applications for clinical trials that may range from small proof-of-concept studies to larger-scale trials, with funding levels set at $2 million for small trials (CTA-FL1) and up to $4 million for larger trials (CTA-FL2). The program emphasizes the importance of addressing the needs of military personnel and veterans, ensuring that proposed studies include diverse patient populations and demonstrate strong preliminary data. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, with an estimated total program funding of $8 million available for approximately three awards. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524MSRPCTA_GG.pdf
    The Department of Defense (DOD) is announcing the Fiscal Year 2024 Multiple Sclerosis Clinical Trial Award (MSRP CTA) under its Congressionally Directed Medical Research Programs. With a funding pool of $20 million, the program invites applications focused on innovative clinical trials that address multiple sclerosis (MS) treatment and management. The submission process includes a two-step requirement: a pre-application due by June 10, 2024, followed by an invited full application by October 7, 2024. Research proposals may explore two principal areas: promoting neuroprotection and repair in MS and treating MS symptoms through various interventions. Eligible applicants include both extramural and intramural organizations, with a principal investigator required to be an independent researcher. Projects can request funding between $2 million for small trials (CTA-FL1) and $4 million for larger trials (CTA-FL2). All proposals must demonstrate relevance to military personnel and veterans, ensuring access to diverse patient populations. The successful implementation of funded trials is expected to significantly impact MS research and patient care, reinforcing DOD's commitment to advancing medical research in service of the military community and the public.
    Similar Opportunities
    Military and Civilian Partnership for Trauma Readiness Grant Program/Mission Zero
    Admin for Strategic Preparedness and Response
    The Administration for Strategic Preparedness and Response is offering the Military and Civilian Partnership for Trauma Readiness Grant Program, also known as the Mission Zero Act, to support high-acuity trauma centers in enhancing military-civilian partnerships for improved trauma care. This grant program aims to award up to 30 eligible trauma centers, enabling military trauma teams to provide full-time trauma and acute care services, thereby strengthening the nation's response to public health and medical emergencies. With an estimated total program funding of $4 million and an award ceiling of $4 million per grant, interested applicants, including nonprofits without 501(c)(3) status and hospitals, should note that the application period is expected to open on January 15, 2025, with a closing date of April 14, 2025. For further inquiries, applicants can contact Leslie Beck at 301-346-4857 or via email at leslie.beck@hhs.gov.
    Fiscal Year (FY) 2026 Department of Defense Multidisciplinary Research Program of the University Research Initiative (MURI) Department of Defense Army
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Fiscal Year 2026 Multidisciplinary Research Program of the University Research Initiative (MURI), aimed at fostering innovative research with military applications. This program invites proposals exclusively from U.S. institutions of higher education, including universities with degree-granting programs in science and engineering, to conduct high-risk basic research that addresses significant scientific challenges. With an estimated total program funding of $170 million over five years, the MURI program will support annual grants of up to $1.5 million, with proposals due by September 5, 2025, and optional white papers due by May 2, 2025. Interested applicants can reach out to Dr. Sue Kase at usarmy.rtp.devcom-arl.mbx.aro-muri@army.mil for further information.
    Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity for clinical trials aimed at addressing unmet needs in rare neurodegenerative diseases through the Notice of Funding Opportunity (NOFO) RFA-FD-25-001. This initiative, mandated by the ACT for ALS Act, seeks to support trials that evaluate the efficacy and safety of products for new indications or changes in labeling, with the goal of increasing the number of approved treatments for these conditions affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various organizations such as higher education institutions and non-profits, with funding amounts capped at $650,000 for standard applications and up to $900,000 for innovative approaches. Interested parties should note that applications will be accepted starting August 23, 2024, with letters of intent and full applications due by October 22, 2024. For further inquiries, applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    NFRP Outreach and Invitation for Response
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) have announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications, specifically requiring clinical trials. This funding opportunity is aimed at U.S. small businesses with the necessary research capabilities to contribute to the missions of the NIH and CDC, encouraging innovation and the commercial viability of health technologies. Eligible applicants can receive funding up to $306,872 for Phase I and $2,045,816 for Phase II, with a submission deadline of April 5, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-246.html.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.